Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors

被引：15
|
作者：
Motzer, R. J. [1 ]
Michaelson, M. D. [2 ]
Hutson, T. E. [3 ]
Tomczak, P. [4 ]
Bukowski, R. M. [5 ]
Rixe, O. [6 ]
Negrier, S. [7 ]
Kim, S. T. [8 ]
Chen, I.
Figlin, R. A. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[4] Klin Onkol Oddzial Chem, Poznan, Poland
[5] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[6] Hop La Pitie Salpetriere, Paris, France
[7] Ctr Leon Berard, Lyon, France
[8] Pfizer Inc, La Jolla, CA USA
[9] City Hope Comprehens Canc Ctr, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71140-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4509
引用
下载
收藏
页码：301 / 301
页数：1
相关论文
共 50 条
  • [31] A PHASE IV MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE THERAPY IN CHINESE PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Qin, S.
    Jin, J.
    Guo, J.
    Wang, J.
    Zhou, F.
    Huang, Y.
    Ren, X.
    Ye, D.
    Wang, Q.
    Pan, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 282 - 282
  • [32] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Sunitinib versus interferon - alfa in metastatic renal-cell carcinoma
    Irani, Jacques
    PROGRES EN UROLOGIE, 2007, 17 (05): : 996 - 996
  • [34] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Rixe, Olivier
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Kim, Sindy T.
    Chen, Isan
    Bycott, Paul W.
    Baum, Charles M.
    Figlin, Robert A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 115 - 124
  • [35] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2S - 2S
  • [37] Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Li, Siming
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Guo, Jun
    ONCOTARGET, 2016, 7 (19) : 27044 - 27054
  • [38] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Pili, Roberto
    Bjarnason, Georg A.
    Garcia-del-Muro, Xavier
    Sosman, Jeffrey A.
    Solska, Ewa
    Wilding, George
    Thompson, John A.
    Kim, Sindy T.
    Chen, Isan
    Huang, Xin
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3584 - 3590
  • [39] Updated Safety and Efficacy Results for Sunitinib From a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma (mRCC)
    Gore, M.
    Porta, C.
    Bracarda, S.
    Crino, L.
    Hawkins, R.
    Bjarnason, G.
    Oudard, S.
    Lee, S. H.
    Kim, T. M.
    Szczylik, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S515 - S515
  • [40] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB (SU) VS SORAFENIB (SFN) AND BEVACIZUMAB plus INTERFERON-ALFA (BEV/IFN) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Diaz, S.
    Aller, E. Calvo
    Maroto, P.
    Puente, J.
    Lopez-Brea, M.
    Castellano, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
12345